1,509 results on '"Sokol, Lubomir"'
Search Results
2. The CNS relapse in T-cell lymphoma index predicts CNS relapse in patients with T- and NK-cell lymphomas
3. Long-term follow up of the combination of ofatumumab, high-dose methylprednisolone, and lenalidomide for untreated chronic lymphocytic leukemia with biomarker analysis
4. Effective treatment with the selective cytokine inhibitor BNZ-1 reveals the cytokine dependency of T-LGL leukemia
5. Sézary syndrome originates from heavily mutated hematopoietic progenitors
6. Toxicity of a Modified PEG-Asparaginase-Based SMILE Regimen Is Comparable to L-Asparaginase-Based SMILE in a Non-Asian Population
7. Multicenter phase 2 study of oral azacitidine (CC-486) plus CHOP as initial treatment for PTCL
8. Brentuximab vedotin plus doxorubicin and dacarbazine in nonbulky limited-stage classical Hodgkin lymphoma
9. Tγδ LGLL identifies a subset with more symptomatic disease: analysis of an international cohort of 137 patients
10. Clinical Response to Upfront Targeted Tyrosine Kinase Inhibitors among Patients with Myeloid/Lymphoid Neoplasms with Eosinophilia and Tyrosine Kinase Gene Fusion
11. Autologous Hematopoietic Cell Transplantation Consolidation for First Response is Associated With Longer Survival Among Patients With Nodal Peripheral T Cell Lymphoma
12. Concurrent enhancer of Zeste homolog 2 (EZH2) over-expression with BRAFV600E mutation predicts a poor outcome in patients with Langerhans cell histiocytosis (LCH): A pilot study.
13. Primary immune thrombocytopenia: a ‘diagnosis of exclusion’?
14. B‐cell maturation antigen expression and clinical features of plasmablastic lymphoma
15. Bendamustine and rituximab as frontline therapy in extranodal marginal zone lymphoma: a single-institution experience
16. Mycosis Fungoides and Sézary Syndrome: Pathogenesis, Diagnosis and Treatment
17. Survival outcomes in blastic plasmacytoid dendritic cell neoplasm by first-line treatment and stem cell transplant
18. Poor Outcome of Adult T-Cell Leukemia/Lymphoma with Current Available Therapy: An Experience of Two Centers
19. Non-del(5q) myelodysplastic syndromes–associated loci detected by SNP-array genome-wide association meta-analysis
20. Oral 5-azacytidine and romidepsin exhibit marked activity in patients with PTCL: a multicenter phase 1 study
21. Chronic lymphocytic leukemia/small lymphocytic lymphoma, version 1.2015.
22. Hematological Malignancies and Arterial Thromboembolism
23. High-dose Therapy and Autologous Hematopoietic Cell Transplantation as Consolidation Treatment for Primary Effusion Lymphoma
24. Brentuximab vedotin, doxorubicin, vinblastine, and dacarbazine for nonbulky limited-stage classical Hodgkin lymphoma
25. T-Cell Large Granular Lymphocytic Leukemia
26. Aggressive Natural Killer Cell Leukemia
27. Extranodal Natural Killer/T-Cell Lymphoma
28. Anaplastic Large Cell Lymphoma
29. Mycosis Fungoides
30. Adult T-Cell Leukemia/Lymphoma
31. Hemophagocytic Lymphohistiocytosis
32. Primary Effusion Lymphoma: Small Bowel Recurrence After Stem Cell Transplant
33. Characterization of myelodysplastic syndromes (MDS) with T-cell large granular lymphocyte proliferations (LGL)
34. MPN-521 Somatic Mutational Landscape and Clinical Response to Upfront Targeted Tyrosine Kinase Inhibitors Among Patients With Myeloid and Lymphoid Neoplasms With Eosinophilia and Rearrangements of PDGFRA, PDGFRB, FGFR1, JAK2, or FLT3
35. Non-Hodgkin's lymphomas, version 4.2014.
36. Phase I evaluation of XL019, an oral, potent, and selective JAK2 inhibitor
37. Mycosis Fungoides Masquerading as Acrodermatitis Continua of Hallopeau
38. Assessment of ASC specks as a putative biomarker of pyroptosis in myelodysplastic syndromes: an observational cohort study
39. A Phase II Trial of Bortezomib and Vorinostat in Mantle Cell Lymphoma and Diffuse Large B-cell Lymphoma
40. Allogeneic hematopoietic cell transplantation in T-cell prolymphocytic leukemia: A single-center experience
41. Clinical Practice Recommendations on Indication and Timing of Hematopoietic Cell Transplantation in Mature T Cell and NK/T Cell Lymphomas: An International Collaborative Effort on Behalf of the Guidelines Committee of the American Society for Blood and Marrow Transplantation
42. Insights into the Impact of Hesitancy on Cancer Care and COVID-19
43. Supplementary Table from Genomic and Single-Cell Landscape Reveals Novel Drivers and Therapeutic Vulnerabilities of Transformed Cutaneous T-cell Lymphoma
44. Abstract 744: Treatment inequities among patients diagnosed with Hodgkin's lymphoma with and without HIV (2018-2019): an analysis of the US National Cancer Database
45. Data from Genomic and Single-Cell Landscape Reveals Novel Drivers and Therapeutic Vulnerabilities of Transformed Cutaneous T-cell Lymphoma
46. Delineation of clinical course, outcomes, and prognostic factors in patients with T‐cell prolymphocytic leukemia
47. Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial
48. The role of anti-PD-1 and anti-PD-L1 agents in the treatment of diffuse large B-cell lymphoma: The future is now
49. The NLRP3 inflammasome functions as a driver of the myelodysplastic syndrome phenotype
50. Figure S1 from A Phase I, Open-Label Study of Siltuximab, an Anti–IL-6 Monoclonal Antibody, in Patients with B-cell Non-Hodgkin Lymphoma, Multiple Myeloma, or Castleman Disease
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.